phosphodiesterase inhibitors

phosphodiesterase inhibitors

Drugs used to prevent inactivation of the cell messenger CYCLIC AMP and thereby increase its stimulating effect on the heart. It is useful to strengthen the heart's action in certain cases of HEART FAILURE. Examples are enoximone (Perfan) and milrinone (Primacor).
References in periodicals archive ?
If evolving NVC changes (In high-risk serological subgroups) are shown to pre-date the emergence of overt organ-specific manifestations of SSc, then we might be provided with a window of opportunity for escalation of therapy with treatments targeting endothelial function (such as phosphodiesterase Inhibitors and/or endothelin receptor antagonists) and/or possible immunomodulatory approaches.
Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis.
The studies on coadministration of alpha-blockers and phosphodiesterase inhibitors have been done in either healthy volunteers, or in patients without severe systemic disease.
Additionally, phosphodiesterase inhibitors such as sildenafil (Viagra) are often used in more severe cases.
Key classes of mechanism of action include endothelin receptor antagonists, platelet aggregation inhibitors, phosphodiesterase inhibitors, serotonin pathway antagonists, angiotensin receptor antagonists, P2Y 12 receptor inhibitors, PDE5 inhibitors, prostacyclin (PGI2) agonists, nitric oxide synthetase inhibitors.
Approval of sildenafil (Viagra) and other type-5 phosphodiesterase inhibitors (vardenafil and tadalafil) for the treatment of erectile dysfunction in men was followed by a series of studies to determine their efficacy in women.
Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review.
Key Words: microvascular surgery, free flaps, milrinone, phosphodiesterase inhibitors, vasospasm
Augmentation of the vasodilatory effects of isosorbide dinitrate by phosphodiesterase inhibitors (e.
Topics of these 19 papers include the physiology and pharmacology of ED and its epidemiology, the pharmacology of phosphodiesterase inhibitors, a five-year review of sildenafil citrate, clinical trials of tadalafil and vardenafil, ED assessment and management in primary practice, special cases such as cardiac or diabetic patients and those with depression, therapies other than oral pharmacology, androgen deficiency, central activation of erection and clinical experience, vacuum devices and implants, prevention of ED, strategies in the management of rapid ejaculation, dysfunction after radical prostatectomy, and the possibilities of oral medications in treating female sexual dysfunction.

Full browser ?